



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support

02 Nov 2021 (#36)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizelk@sun.ac.za

Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

Notices

[NOT-OD-22-018](#) FORMS-G Grant Application Forms & Instructions Must be Used for Due Dates On or After January 25, 2022 - New Grant Application Instructions Now Available. This Notice reminds the applicant and recipient community that applicants must use FORMS-G application packages for due dates on or after January 25, 2022 and must use FORMS-F application packages for due dates on or before January 24, 2022 (see [NOT-OD-21-169](#) for details). All significant changes to form instructions are listed at: <https://grants.nih.gov/grants/how-to-apply-application-guide/forms-g/general/g.120-significant-changes.htm>.

[NOT-OD-22-008](#) Guidance electronic Research Administration (eRA) Research Performance Progress Report (RPPR) Submission Validations for Clinical Trial Registration and Results Reporting. The purpose of this Notice is to notify the extramural research community of the implementation of updated eRA Research Performance Progress Report (RPPR) submission system validations for clinical trial registration and results reporting as of October 1, 2021. These validations will impact the recipient's ability to submit RPPRs when the associated clinical trials are non-compliant with clinical trial registration and results reporting requirements found in Federal regulations in Section 801 of the Food and Drug Administration Amendments Act (FDAAA) as implemented by [42 CFR Part 11](#) (Final Rule) and/or the NIH Grants Policy Statement (NIHGPS), a term and condition of all NIH grant awards, section [4.1.3.1 - NIH Policy on the Dissemination of NIH-Funded Clinical Trial Information](#).

Notices of Special Interest

NOT-HL-22-001: IDEA2Health: Innovative Data Evaluation and Analysis to Health. The purpose of this Notice of Special Interest (NOSI) is to stimulate research and advancement of methodologies in data science in heart, lung, blood, or sleep (HLBS) biomedical research, and ultimately translate new insights into decision-making to improve health. For this NOSI, NHLBI will only accept applications in response to [PA-20-183](#) and [PA-20-185](#). For [PA-20-183](#), only **mechanistic** clinical trials will be accepted in accordance with [NOT-HL-19-690](#). Applicants wishing to propose non-mechanistic clinical trials may consider applying to one of the NHLBI clinical trial mechanisms described at <https://www.nhlbi.nih.gov/grants-and-training/clinical-trial-development-continuum>. Non-mechanistic clinical trials submitted in response to this NOSI via [PA-20-183](#) will be withdrawn. Potential applicants requesting \$500,000 or more in direct costs in any year (excluding consortium F&A) must consult NHLBI program staff and submit a letter of request to the NHLBI prior to submitting any applications. Investigators planning to submit an application in response to this NOSI are **strongly encouraged** to contact and discuss their proposed research/aims with an NHLBI program officer listed on this NOSI well in advance of the grant receipt date.

Funding Opportunity Announcements (FOA)

1. Understanding the Role of Bilingualism in Cognitive Reserve/Resilience in Aging and AD/ADRD (R01 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-AG-23-001](#)

Type: R01

Application Due Date: March 03, 2022. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: The goal of this Funding Opportunity Announcement (FOA) is to support research studying the role of bilingualism as it relates to cognitive reserve/resilience in healthy aging and in Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD). This FOA aims to address the need for more prospective, hypothesis-driven research to build a theoretical framework and to clearly identify the extent to which acquiring a second language impacts human brain function. Multimodal and multidisciplinary studies are highly encouraged to improve our understanding of the complex interactions between neural, environmental, and sociocultural factors and the role of bilingualism in healthy aging and in AD/ADRD.

Budget: NIA intends to commit \$6,000,000 in FY 2023 to fund 6-10 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

2. Cell-Specific Impact of Liquid-Liquid Phase Separation in Aging and AD/ADRD (R21 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-AG-23-002](#)

Type: R21

Application Due Date: March 03, 2022. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: The goal of this Funding Opportunity Announcement (FOA) is to support research to identify cell-specific mechanisms in biomolecular condensate (BMC) formation and function, providing novel information for the role BMCs play in diverse cell types in the context of aging and neurobiology of Alzheimer's disease (AD) or AD-related dementias (ADRD). This research should enhance our understanding of the cell-specific mechanistic role of BMCs in aging and AD/ADRD and serve as the foundation for more comprehensive etiological studies that might lead to the development of future BMC-based therapies for age-related neurodegenerative diseases.

Budget: NIA intends to commit \$2.5 million in FY 2023 to fund 8-10 awards. The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year.

3. Research Bases for HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network (UG1 Clinical Trial Required)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-CA-21-046](#)

Type: UG1

Application Due Date: December 28, 2021. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) solicits applications from institutions/organizations to participate as the Research Bases for the HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network. The 'CASCADE' network will conduct pragmatic clinical trials evaluating the effectiveness of clinically proven interventions to overcome barriers and reduce failures in the cervical cancer screening, management, and precancer treatment cascade for women living with HIV. 'CASCADE' clinical trials will be conducted in intended-use environments in resource-constrained settings in low- and middle-income countries and in regions with health disparities in the United States, and will have four major scientific focus areas: increasing screening uptake, improving the management of screen positives, facilitating precancer treatment access, and optimizing precancer treatments for cervical cancer prevention in women living with HIV. Evidence from these trials is expected to inform clinical practice guidelines and improve the implementation of cervical cancer prevention and control programs globally. 'CASCADE' will consist of three organizational components each with its own FOA: U24 Coordinating Center ([RFA-CA-21-045](#)), UG1 Research Bases (this FOA), and UG1 Clinical Sites ([RFA-CA-21-047](#)). As an integral part of this Cooperative Agreement-funded network, the UG1 Research Bases (this FOA) will (i) provide scientific and statistical leadership for developing network clinical trials concepts and protocols, overseeing their conduct, and analyzing and publishing their results, (ii) ensure compliance with human research participant protection and other regulatory and administrative reporting requirements, and (iii) work towards creating opportunities for training emerging investigators.

Budget: NCI intends to commit \$1.5 million per year total costs in FY2022 to fund up to three awards for the UG1 Research Bases. It is expected that \$1.5 million per year will be available in FY2023 - FY2026, but future year amounts will depend on annual appropriations. The requested budget must not exceed \$400,000 in direct costs for each year of the 5-year project period. The maximum project period is 5 years.

4. Home and Community-Based Physical Activity Interventions to Improve the Health of Wheelchair Users (R01 Clinical Trial Required)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-HD-22-017](#)

Type: R01

Application Due Date: March 30, 2022. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: The purpose of this funding opportunity announcement (FOA) is to request applications to develop/adapt and test physical activity interventions for individuals who use wheelchairs due to physical disability. The goal of the proposed interventions should be to safely prevent, or reverse chronic conditions associated with low physical activity such as diabetes, cardiovascular disease, and obesity. Inclusion criteria and stratification must be based on functional status rather than the primary condition leading to disability. Interventions that could be applied or easily adapted to large populations of wheelchair users and used in multiple settings are a priority.

Budget: NICHD intends to commit \$1.5 million in FY 2023 to fund 3 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

5. Elucidating the Role of Nutrition in Care and Development of Preterm Infants (R01 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-HD-22-023](#)

Type: R01

Application Due Date: March 30, 2022. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) invites grant applications that address priority gaps in understanding the role of nutrition in the care and development of preterm infants.

Budget: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. NICHD intends to commit \$1,000,000 in FY 2022 to fund 1-4 awards. Application budgets are limited to \$499,999 direct costs per year (exclusive of subcontracts F&A) and need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 4 years.

6. Promoting Reproductive Health for Adolescents and Adults with Disabilities (R01 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-HD-23-005](#)

Type: R01

Application Due Date: March 30, 2022. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) invites grant applications that address gaps in our understanding of best practices for promoting reproductive health across the transition from adolescence to adulthood for persons with disabilities.

Budget: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. NICHD intends to commit \$2,000,000 in FY 2023 to fund 3-4 awards. ORWH intends to commit \$100K in FY 2023. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

7. Cellular Senescence Network: Technology Development and Application in Murine Systems (UG3/UH3 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-RM-22-005](#)

Type: UG3/UH3

Application Due Date: January 19, 2022. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: The purpose of this FOA is to solicit novel analytics and technologies to identify and map senescent cells in murine tissues at high resolution. This FOA supports the accelerated proof-of-principle demonstration of promising tools, techniques and methods that can be integrated, scaled, and applied to multiple murine tissues. The initial two-year UG3 phase will support the development and demonstration of feasibility of these emerging technologies in the identification and mapping of senescent cells in murine tissues. The subsequent UH3 phase is to support initial validation in multiple murine and/or human tissues, optimization and scale-up, generation of production level data and the application of the technology to describe cellular senescence in a mouse life course situation (for example development or lifespan). Investigators responding to this FOA must submit both UG3 and UH3 projects as part of a single application. UG3 projects that have met their quantifiable milestones will be administratively considered by NIH staff and prioritized for transition to the UH3 phase, depending on the availability of funds.

Budget: The NIH Common Fund (Office of Strategic Coordination) intends to commit \$1.5M Total Costs in FY 2022 to fund up to 3 awards. The awards are contingent upon NIH appropriations and the submission of sufficiently meritorious applications. Application budgets are not limited but must reflect the actual needs of the proposed project. Applications should not exceed \$350,000 in direct costs per year during the UG3 phase and \$500,000 in direct costs per year during the UH3 phase. The proposed project period for the UG3 phase may not exceed 2 years and the UH3 phase may not exceed 3 years. The total duration of UG3 plus UH3 phases may not exceed 4 years.

Research Development and Support Division (RDSD),
Faculty of Medicine and Health Sciences, Stellenbosch University
5th Floor, Teaching Block, Tygerberg Campus.
Enquiries: *Christa*
e: cdevries@sun.ac.za | t: +27 21 938 9838

Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)
Stellenbosch University
2038 Wilcocks Building, Ryneveld Street
Enquiries: *Lizél*
e: lizelk@sun.ac.za | t: +27 21 808 2105